REmote moBile Outpatient mOnitoring in Transplant 2.0

Overview

This study is designed to determine if an innovative mobile health intervention designed to improve patient-provider communication can reduce unscheduled hospitalizations, and visits to the emergency department and ambulatory clinic in adult heart, liver, and kidney transplant patients.

Full Title of Study: “REmote moBile Outpatient mOnitoring in Transplant (Reboot) 2.0”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Single (Participant)
  • Study Primary Completion Date: September 2025

Detailed Description

Mobile health technologies such as smartphones and wearable devices can remotely monitor health. These technologies hold promise to improve health outcomes in a spectrum of patients by providing health care teams with better connectivity which may prompt more timely responses to questions and improvements to care. The purpose of this study is to evaluate if solid organ transplant (SOT) recipients benefit from improved monitoring and removal of communication barriers as the most common reasons for readmission and mortality may be mitigated by clinical intervention. Additionally, medication adherence is critical in transplant patients to prevent graft rejection. We anticipate that remote monitoring will improve medication adherence/adjustments, and will allow for identification of early health issues, reducing preventable hospital readmissions. Thus, this study will determine if an innovative mobile health intervention, designed to improve patient-clinician communication, reduces unnecessary hospital readmission and visits to the emergency department and transplant clinic when utilized in addition to the standard of care telephone communication system. We will also incorporate clinical and continuous ambulatory physiologic data collected as part of the mobile health intervention to develop machine learning algorithms capable of identifying early indicators of adverse outcomes in adult heart, kidney, and liver transplant patients. We hypothesize that: the delivery of personalized communication using a mobile health application will improve patient self-management resulting in a 50% reduction in preventable hospital readmission, and unscheduled visits to the emergency department and transplant clinic. With tailored communication through the mobile health application, we expect fewer standard of care phone messages for patients in the intervention group and patients with higher activity levels (average daily step-count) pre-transplantation will have lower index hospitalization length of stay. Finally, the large dataset collected from this study will allow novel machine learning-derived risk prediction models to more accurately predict adverse outcomes (e.g., organ rejection, infection, and death), compared to conventional regression models.

Interventions

  • Other: Active communication through Reboot application
    • Access to active communication with the transplant care team through Reboot application based asynchronous messaging for non-urgent issues, as well as personalized clinical notifications.
  • Other: Generic communication through Reboot application
    • Access to generic messaging through Reboot application, and communication with the transplant care team through standard of care communication system.

Arms, Groups and Cohorts

  • Experimental: Intervention Group
    • 1 year of tailored communication with transplant care team through Reboot application in addition to standard of care communication system.
  • Sham Comparator: Standard of Care Group
    • 1 year of generic communication through Reboot application with communication with transplant care team through standard of care communication system.

Clinical Trial Outcome Measures

Primary Measures

  • Unscheduled hospital admission or visit to emergency department or transplant clinic.
    • Time Frame: 1-month
    • A composite score of unscheduled hospital admission, visit to the emergency department or ambulatory transplant clinic (i.e., total number of visits) will be calculated for each group at the pre-specified time intervals. A central adjudication committee will assess each readmission and visit to determine if they constitute a study event.

Secondary Measures

  • EuroQol-5 (EQ-5D) Dimension questionnaire
    • Time Frame: 1-month, 3-months, 12-months
    • The EQ-5D is a comprehensive and compact health status classification and health state preference questionnaire, widely used in many patient populations.
  • Patient-Reported Outcomes Measurement Information System (PROMIS) tool
    • Time Frame: 1-month, 3-months, 12-months
    • PROMIS is a single patient-centered questionnaire that measures and monitors several domains, including physical, mental, and social health. It is validated for use with the general population and individuals living with chronic disease.
  • Graft survival rate
    • Time Frame: 12-months
    • Transplanted organ survival rate will be calculated for each group at the end of the study period.
  • Patient survival rate
    • Time Frame: 12-months
    • Patient survival rate will be calculated for each group at the end of the study period.
  • Easy Call interactions
    • Time Frame: 1-month, 3-months, 12-months
    • The number of interactions that each group has with standard of care communication system (‘Easy Call’) will be compared.
  • Index hospitalization length of stay
    • Time Frame: 1-month
    • Participants activity level while on the transplant waiting list will be quantified by their average daily step count, and compared to the length of their index hospitalization.

Participating in This Clinical Trial

Inclusion Criteria

  • Solid organ (heart, liver, or kidney) transplant patients – The ability to use a smartphone – English speaking Exclusion Criteria:

  • Poor health literacy (reading level less than grade 5) – Inability to follow instructions from the Reboot application – Transfer to a non-University Health Network Hospital for follow-up and management

Gender Eligibility: All

Minimum Age: 21 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Health Network, Toronto
  • Provider of Information About this Clinical Study
    • Principal Investigator: Heather Ross, Head, Division of Cardiology – University Health Network, Toronto
  • Overall Official(s)
    • Heather Ross, MD, Principal Investigator, University Health Network, Toronto
  • Overall Contact(s)
    • Yasbanoo Moayedi, MD, 416-340-4800, yas.moayedi@uhn.ca

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.